A Novel Botanical Supercharged Wound Hydrogel to Prevent Diabetic Wound-Related Amputations

Dr. Oscar Barreto discusses background and insights from his poster, “Preventing Amputation: Successful Management and Expedited Healing of Diabetic Wounds with Novel Botanical Supercharged Wound Hydrogel,” presented at SAWC Fall 2023 in Las Vegas, NV.
 

Transcript

Oscar Barreto, DPM, AGNP

Good afternoon. My name is Dr. Oscar Barreto. I am a wound specialist here in the Miami area, Florida. I've been in the wound management world since 1996. And, presently, I've been working with this new medication of Lavior, which is a botanical medication that has worked very well for my patients.

The patient that I've presented for the poster is a patient with a medial malleolus venous ulcer. This is a 46-year-old male with a history of HIV and sickle cell anemia, with also a history of deep venous thrombosis, who actually had been managed with other modalities. And once he came into my care, I converted him to the Lavior gel management. And we started it on December 7, 2022, and, by 3/27/2023, we have had a complete closure. One of the important parts of this management was that immediately when I started using the gel, the patient had an immediate relief of localized pain, and went on to heal pretty much uneventfully.

The fact that he had those underlying conditions, especially the sickle anemia, his HIV was under, well controlled with medication, but the fact that he had told me that this had been recurrent, and he had been managed previously by other physicians with other modalities, and he even came back to me within a couple of weeks of starting the management and said how well he saw the improvement and how good he felt. So I felt, at that point, well, maybe this is something that, you know, we should tell and bring it to the attention of all the practitioners.

What it is is a botanical. And what it does, it has a great anti-inflammatory component. With that anti-inflammatory component, what it does, it helps take the wound from the inflammatory phase and pass it to the proliferative phase faster. Obviously, we need the inflammatory phase because we need those inflammation processes to bring white cells and all the macrophages and mass cells as well as, you know, growth factors to help. However, it doesn't allow it to linger in that inflammatory phase, making the wound chronic, which is usually one of the problems that we fall into with these venous ulcers. They become chronic, and once that happens, then we, you know, we have a problem. What I found that while using Lavior, that stage was limited. So, it went pretty fast into the proliferative phase where the healing occurs.

Again, it was the speed and the relief of symptomatology. I felt that, immediately, the inflammatory phase was reduced. The patient did give a positiveness as far as, you know, “I have less pain. I'm able to move a lot better.” So, that was something that attracted me.

I believe that the future is definitely it should be bright. I found no adverse reaction in the patients that that I've used it on. I found that it was very easy to apply. It was affordable. That was one of the things that in today's world I find. You know, there's a lot of modalities out there, but affordability is important, so we're able to you know, with this product, I'm able to alleviate a lot of the patients that might not be able to obtain the more expensive managements.